Sri Obulareddy, MD
Medical Oncology · Yakima, WANPI 1760779979
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $235 of the $323 with a category attached, or 72.7%. 9 manufacturers reported payments, led by AbbVie at 33.7% of the total. Reporting peaked in 2019 at $146 and has fallen 63.3% since, to $53 in 2023. That places this record below the midpoint for medical oncology clinicians in WA, where the typical reported total is $2,355.
Across 9 payments — averaging $35.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$109
- GSK$62
- Genentech, Inc.$53
- Myovant Sciences Inc.$24
- Takeda Pharmaceuticals U.S.A., Inc.$23
- E.r. Squibb & Sons, L.L.C.$16
- plus $36 from 3 others
Across 58 payments — averaging $7503.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$379K
- Amgen$16K
- AbbVie$15K
- Pfizer$10K
- Incyte Corporation$6K
- Pharmacyclics LLC, An Abbvie Company$6K
- plus $2K from 2 others
What the payments were for
- Food & beverage$23573%
- Education$8827%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 1 | $109 |
| GSK | 1 | $62 |
| Genentech, Inc. | 1 | $53 |
| Myovant Sciences Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Seagen Inc. | 1 | $14 |
| Morphosys, US Inc. | 1 | $11 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Venclexta$109
How this compares
$323 in reported general payments places this provider in the 30th percentile of 162 medical oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 28 | $456,449 |
| VerzenioAbemaciclib | 13 | $195,151 |
| XareltoRivaroxaban | 14 | $13,144 |
| Tamoxifen Citrate | 61 | $1,190 |
| Anastrozole | 91 | $1,148 |
| Prochlorperazine Maleate | 36 | $987 |
| Ondansetron OdtOndansetron | 48 | $972 |
| Letrozole | 48 | $725 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 18 | $237 |
| Potassium Chloride | 39 | $231 |
| Gabapentin | 19 | $144 |
| Oxycodone Hcl | 11 | $131 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Yakima
- Hakan KayaSpokane$2.2M
- Bart ScottSeattle$1.3M
- William BensingerLakewood$1.2M
- Petros GrivasSeattle$628K
- Vijayakrishna GadiSeattle$573K
- Evan YuSeattle$296K
- Siddhartha DevarakondaSeattle$215K
- David MaloneySeattle$150K
- Gary LymanSeattle$130K
- Joseph YeOlympia$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.